Antiemetic Guideline 2016 SUMMARY Multinational Association of Supportive Care in Cancer Organizing and Overall Meeting Chairs Matti Aapro MD Richard J Gralla MD Jørn ID: 538261
Download Presentation The PPT/PDF document "MASCC/ESMO" is the property of its rightful owner. Permission is granted to download and print the materials on this web site for personal, non-commercial use only, and to display it on your personal computer provided you do not modify the materials and that you retain all copyright notices contained in the materials. By downloading content from our website, you accept the terms of this agreement.
Slide1
MASCC/ESMO Antiemetic Guideline 2016SUMMARY
Multinational Association of Supportive Care in CancerOrganizing and Overall Meeting Chairs:Matti Aapro, MDRichard J. Gralla, MDJørn Herrstedt, MD, DMSciAlex Molassiotis, RN, PhDFausto Roila, MD
© Multinational Association of Supportive Care in
Cancer
TM All rights reserved worldwide.
1
2016 V.1.1Slide2
Matti Aapro, MD
Enzo Ballatori, PhD Mary Jacqueline Brames, RN, BSNEduardo Bruera, MDAlex Chan, PharmDLuigi Celio, MDRebecca Clark-Snow, RN, BSNAndrew Davies, MDMellar Davis, MDKristopher Dennis, MDL. Lee Dupuis, RPh, PhDLawrence Einhorn, MDPetra
Feyer, MD
Richard
Gralla, MDJørn Herrstedt, MD, DMSci
Paul Hesketh
, MD
Regine
Deniel Ihlen (patient advocate)Franziska Jahn, MDKarin Jordan, MDErnesto Maranzano, MDAlexander Molassiotis, RN, PhDRudolph Navari, MD, PhDIan Olver, MD, PhDAndrea Orsey, MDBernardo Rapoport, MDCynthia Rittenberg, RN, MN
2015 Copenhagen Antiemetic Guideline Comittee Participants
Carla Ripamonti, MDJoseph Roscoe, PhDFausto Roila, MDChristina Ruhlmann, MD, PhDWim Tissing, MDMitsue Saito, MDLee Schwartzberg, MDLillian Sung, MD, PhDDeclan Walsh, MDDavid Warr, MDMarianne van de Wetering, PhDTheresa Zanatta (patient advocate)Li Zhang, MD
2
2016 V.1.1
These slides are provided to all by the Multinational Association of Supportive Care in Cancer and can be used freely, provided no changes are made and the MASCC and ESMO logos, as well as date of the information are retained.
For questions please
contact:
Matti
Aapro
at
maapro@genolier.net
Chair
, MASCC Antiemetic Study Group
or Alex
Molassiotis
at
alex.molasiotis@
polyu.edu.hk
Past
Chair, MASCC Antiemetic Study
GroupSlide3
EMETIC RISK GROUP
ANTIEMETICSHigh Non-AC
High AC
Carboplatin
Moderate
(other than carboplatin)
Low
Minimal
No routine prophylaxis
ACUTE
Nausea and Vomiting: SUMMARY32016 V.1.15-HT3
DEX
NK
1
+
+
5-HT
3
DEX
NK
1
+
+
5-HT
3
DEX
NK
1
+
+
5-HT
3
DEX
+
5-HT
3
DEX
DOP
or
or
5-
HT
3
= serotonin
3
receptor antagonist
DEX
= DEXAMETHASONE
DOP = dopamine receptor antagonist
NK1 = neurokinin1 receptor antagonist such as APREPITANT or FOSAPREPITANT or ROLAPITANT or NEPA (combination of netupitant and palonosetron)
NOTE:
If the NK
1
receptor antagonist is not available for AC chemotherapy,
palonosetron
is
the preferred
5-HT
3
receptor antagonist.Slide4
EMETIC RISK GROUP
ANTIEMETICSHigh Non-AC or ( if APR 125mg for acute: ( + ) or )
High AC
None or ( if APR 125mg for acute: or )
Carboplatin
None or ( if APR 125mg for acute: )
Oxaliplatin
,
or anthracycline,
or cyclophosphamide
Moderate (other)No routine prophylaxisLow and MinimalNo routine prophylaxisDELAYED Nausea and Vomiting: SUMMARY42016 V.1.1 DEX can be considered
DEX
= DEXAMETHASONE
APR
= APREPITANT
MCP
= METOCLOPRAMIDE
MCP
DEX
APR
DEX
DEX
APR
APRSlide5
MASCC/ESMO Antiemetic Guideline 2016
© 2016 Multinational Association of Supportive Care in CancerTM All rights reserved worldwide. 52016 V.1.1